Enjoy complimentary customisation on priority with our Enterprise License!
The hereditary angioedema (HAE) therapeutics market size is estimated to grow by USD 1.65 billion at a CAGR of 8.95% between 2022 and 2027.
One of the factors contributing to the rise in hereditary angioedema prevalence is improved awareness and diagnosis. In the past, hereditary angioedema was frequently misdiagnosed or undiagnosed altogether, leading to an underestimation of its prevalence. More cases of hereditary Angioedema are being recognized and reported due to increased awareness among healthcare professionals and improved diagnostic tools. Furthermore, its increased incidence was also due to a more intensive study and a further understanding of hematological angioedema. As scientists and healthcare professionals gain a better understanding of the genetic basis and primary mechanisms of hereditary angioedema, they are able to identify more individuals with the condition. This increased knowledge has also led to better education and awareness among the general population, prompting individuals with symptoms of hereditary angioedema to seek medical attention and receive an accurate diagnosis. Such factors will increase the market growth during the forecast period.
To learn more about this report, Request Free Sample
The market focuses on addressing symptoms like edema in hands and feet caused by deficiencies in the C1 esterase inhibitor (C1-INH). Therapeutic interventions target blood vessels and involve treatments such as synthesis of inhibitor and managing spontaneous mutation in the C1 inhibitor gene. Various medications fall under the drug class, and they are made accessible through distribution channel like retail pharmacy to ensure widespread availability and access to treatment options.
Technavio has segmented the market by the End-user segment is classified into hospital pharmacies, retail pharmacies, and e-commerce. The product segment is classified into C1-esterase inhibitor, bradykinin B2 receptor antagonist, kallikrein inhibitor, and others. Also, the geography segment includes key regions such as North America, Europe, Asia, and the Rest of the World (ROW)
The market share by the hospital pharmacies segment will be significant during the forecast period. Hospital pharmacies play a crucial role in the hereditary angioedema (HAE) therapeutics market. Hospital pharmacies are becoming pivotal in providing the necessary medicines and treatments for patients with hereditary angioedema, due to the rise in prevalence of hereditary angioedema.
Get a glance at the market contribution of various segments View a PDF Sample
The hospital pharmacies segment was valued at USD 991.73 million in 2017. Hospital pharmacies must actively engage in sourcing these medications from reliable suppliers to ensure they have sufficient stock to meet the demands of hereditary angioedema patients. Moreover, hospital pharmacies play a key role in dispensing these medications to hereditary angioedema patients. They have direct interaction with patients and their healthcare providers so they can ensure prescriptions, as well as provide necessary guidance for the use of medication.
C1-esterase inhibitors are a key component in the market. These inhibitors are crucial in managing and treating this rare genetic disorder by preventing attacks of angioedema. C1 Inhibitors work by inhibiting the C1 protein in the complement system, which is part of the immune system in the human body. The complement system is a major component of the immune system, but in people with hereditary angioedema, it begins to be activated and may result in episodes of severe swelling across all parts of the body, including the face, hand, foot, or gastrointestinal tract. The C1 Inhibitors segment of the hereditary angioedema (HAE) therapeutics market has been growing rapidly in recent years. Increased realization and diagnosis of hereditary angioedema, along with the development of new and improved C1 Inhibitor therapies, have contributed to this growth. Thus, it is expected to increase the demand for C1 Inhibitors among patients with hereditary angioedema, which will drive the growth of the market.
For more insights about the market share of various regions View PDF Sample now!
North America is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America holds a significant position in the global hereditary angioedema (HAE) therapeutics market. Hereditary angioedema is a rare genetic disorder characterized by recurring episodes of swelling in different parts of the body, including the hands, feet, face, and airways. The region plays a major role in the market due to its strong medical infrastructure, considerable R&D efforts, and large prevalence of hereditary angioedema.
North America provides world-class medical facilities and has a well-developed pharmaceutical industry. This enables advanced diagnostic capabilities, improved treatment options, and the effective management of the disease for patients with hereditary angioedema. Innovation and advancement of treatment options are being encouraged by the large research and development activities in North America related to therapies for hematological angioedema. Numerous pharmaceutical companies in the region are actively involved in developing novel drugs and therapies to address the specific needs of patients with such issues. Such factors will increase the market growth in this region during the forecast period.
Buy Now Full Report and Discover More
The market addresses conditions like Type I HAE, Type II HAE, and Type III HAE, characterized by edema due to C1 esterase inhibitor (C1-INH) deficiency. Treatment involves managing symptoms and preventing attacks through therapy, including donidalorsen and Kallikrein inhibitors. Physicians, including dermatologists, gastroenterologists, and clinical allergists, play pivotal roles. With options like oral medications and prophylaxis, patients seek relief through various distribution channels, including retail pharmacies. Treatment decisions often consider family history and dysfunctional protein synthesis to tailor therapeutic approaches. There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key trends and challenges.
The growing demand for personalized medicine is a key trend in the market. The increasing prevalence of hereditary angioedema and the need for more effectual and targeted treatments support the market. Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of swelling in various parts of the body. These episodes may have unpredictable and debilitating effects on the patient, causing significant pain, discomfort, or functional impairment. Traditionally, the treatment options have been limited, with most focusing on managing the symptoms and preventing severe attacks.
However, advancements in personalized medicine have opened up new possibilities for the treatment of hereditary angioedema. Personalized medicine can lead to a more targeted approach to treatment and the reduction of frequency and severity of attacks, as far as hematological angioedema is concerned. Thus, these factors are expected to increase the demand for personalized medicine, which will drive the growth of the market during the forecast period.
The high cost associated with the development and production is a major challenge in the market growth. The market has seen exceptional development in recent years, with new treatments offering hope to patients diagnosed with this rare genetic disorder. In order to guarantee the safety and efficacy of new therapeutic products for hereditary angioedema, a large amount of research and clinical trials are needed. These processes involve substantial capital investments, which are then reflected in the final cost of the product.
Additionally, the cost of conducting multiple parts of clinical trials, which range from initial safety assessments to large-scale efficacy studies, can be substantial. Marketing efforts are required to educate healthcare professionals and patients about the therapeutics, while distribution costs are incurred on ensuring that the products reach the target population. Furthermore, in order to monitor the safety and efficacy of therapeutic products once they have been placed on the market, post-marketing surveillance is essential. Thus, such factors are expected to hinder the growth of the market focus during the forecast period.
Buy Now Full Report and Discover More
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market forecasting report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 16 market companies, including:
Adverum Biotechnologies Inc. - The company initiated preclinical treatment of ADVM 053, which has been approved by the FDA and ODD ADVM 053.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
The market addresses the critical needs of patients experiencing angioedema attack, offering treatments to alleviate symptoms and improve quality of life. Despite challenges like misdiagnosis and allergic reaction, advancements in intravenous and subcutaneous therapies such as Cinryze, Kalbitor, and Firazyr have transformed care. Emerging options like Orladeyo and Takhzyro, including B2 bradykinin receptor antagonists and tranexamic acid, provide promising alternatives. With a focus on market player and pipeline medications, the industry aims to address the unmet needs of those affected by rare diseases through innovative subcutaneous injections and monoclonal antibodies like lanadelumab.
Further, the market addresses the urgent needs of patients with HAE by offering a range of treatments to manage symptoms and improve quality of life. Despite challenges such as allergic reactions and the risk of appendicitis, patients have access to various options, including SAJAZIR Injection, Ruconest, Icatibant, and Berinert, which provide relief during angioedema attacks. Emerging therapies like Haegarda and attenuated androgens offer promising alternatives alongside intravenous treatments and ACE inhibitors. Market players in the rare illnesses industry continue to innovate to address unmet needs in HAE treatment, including those associated with irritable bowel syndrome (IBS) and allergies.
Market Scope |
|
Report Coverage |
Details |
Page number |
156 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 8.95% |
Market growth 2023-2027 |
USD 1.65 billion |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
8.81 |
Regional analysis |
North America, Europe, Asia, and the Rest of the World (ROW) |
Performing market contribution |
North America at 38% |
Key countries |
US, Canada, Germany, China, and India |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Attune Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., CENTOGENE NV, Cipla Ltd., CSL Ltd., Diapharma Group Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Pharming Group NV, Pharvaris NV, Sanofi, and Takeda Pharmaceutical Co. Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.